BXRX - Baudax Bio, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
-0.32 (-3.74%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close8.55
Bid8.24 x 900
Ask8.77 x 800
Day's Range8.20 - 8.68
52 Week Range3.57 - 9.60
Avg. Volume192,103
Market Cap76.956M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateFeb 12, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.67
  • GlobeNewswire

    Baudax Bio Reports 2019 Annual Financial Results

    FDA Grants Appeal for IV Meloxicam New Drug Application PDUFA Goal Date of February 20, 2020 MALVERN, Pa., Feb. 13, 2020 -- Baudax Bio, Inc. (NASDAQ:BXRX), a.

  • GlobeNewswire

    Baudax Bio Announces PDUFA Date for Intravenous Meloxicam

    Baudax Bio, Inc. (BXRX), a specialty pharmaceutical company focused on therapeutics for acute care settings, today announced that the U.S. Food and Drug Administration (FDA) has set a PDUFA goal date of February 20, 2020 for its decision on the New Drug Application (NDA) for intravenous (IV) meloxicam for the management of moderate to severe pain. The assignment of this PDUFA goal date follows the FDA’s acceptance of Baudax’s latest complete response package relating to its 2019 complete response letter (CRL) and appeal filing, seeking approval for IV meloxicam.